Blog

Registration now open for the multi-day event that showcases the Empire State’s latest disruptive technologies

ROCHESTER, NY / ACCESS Newswire / July 24, 2025 / The New York State Innovation Summit will return to the Rochester Riverside Convention Center on October 29-30. Presented by FuzeHub, in partnership with Empire State Development’s Division of Science, Technology & Innovation (NYSTAR), the New York State Innovation Summit is the premier gathering of technology leaders, manufacturers, researchers and entrepreneurs shaping the future of American innovation. Delivering the keynote addresses this year will be leaders from the United States Air Force Research Laboratory, SEMI Americas and Applied Materials, Inc.

With more than 550 participants expected – including over 50 speakers and exhibitors – the summit will celebrate technology-led economic growth while providing an unparalleled platform for New York’s companies and innovators to showcase products, forge strategic partnerships, and accelerate the commercialization of tomorrow’s game-changing technologies. The ninth annual New York State Commercialization Competition will also take place, with companies throughout the state competing to demonstrate the potential of their technology or product – inspiring even more innovation from the halls of the summit.

Summit attendees will hear from experts across a vast array of topics, including cell and gene therapy, AI, the future of glass as an advanced material, technology meeting fashion, venture capital, manufacturing advancements, and so much more. The 2025 keynote speakers are:

• Dr. Michael J. Hayduk, deputy director, information directorate, Air Force Research Laboratory. Attendees will hear from Dr. Hayduk, who has led the work of over 1,200 scientists, engineers, administrative and support personnel in his role, in addition to overseeing an annual budget of over $1.6 billion. He was also critical to opening an innovation technology hub outside of the security perimeter of the Information Directorate.

• Joe Stockunas, president, SEMI Americas. Stockunas joined SEMI – the global industry association with over a million professionals worldwide that unites the entire semiconductor, electronics and manufacturing and design supply chain-in 2022 to increase the value SEMI delivers to 3,000 member companies, direct North America services and drive programming. He is also an advocate for the microelectronics industry as part of the company’s global leadership team, which he’ll discuss at the conference.

• Dr. Omkaram Nalamasu, Ph. D., senior vice president and chief technology officer, Applied Materials, Inc. Dr. Nalamasu leads the development of disruptive products to address new markets and businesses in partnership with the broader technology system. He has built an impressive team to support Applied Materials’ leadership in materials engineering, has earned recognition among his peers as a world-renowned expert in materials science, and is one of the industry’s most respected forward-thinkers.

“For six years and counting, the New York State Innovation Summit has attracted the most impressive leaders, companies and researchers who are at the forefront of emerging technologies and game-changing discoveries in the Empire State,” said FuzeHub Executive Director Elena Garuc. “The greater Rochester region is deeply rooted in the history of American manufacturing and ingenuity, which makes it a natural meeting place to convene the state’s ecosystem of innovation professionals as we continue to foster collaborations that shape the future.”

FuzeHub, which serves as the statewide center of the New York Manufacturing Extension Partnership (NY MEP), has organized the New York State Innovation Summit for the last six years as part of its enduring commitment to fostering innovation, technology development, and breakthroughs in manufacturing across the state.

Born from the longstanding tradition of uniting NYSTAR-supported innovation resources, the summit has grown into a dynamic forum where critical conversations about technology convergence, emerging markets, and manufacturing excellence take center stage. New York’s brightest minds don’t just discuss the future of innovation at this event-they actively create it, fostering progress and positioning the Empire State as a global leader in the technologies that matter most.

The annual summit ignites new conversations about the latest market trends, opportunities, challenges and solutions – ultimately propelling New York’s innovation ecosystem forward,” said NYSTAR Executive Director Ben Verschueren. “It’s the largest gathering of our ecosystem every year, and we are looking forward to being part of it once again alongside our partners at FuzeHub to celebrate the cutting-edge ideas that can impact communities far beyond our state.

To follow the latest 2025 New York State Innovation Summit speaker updates and to register, visit nysinnovationsummit.com. All industry professionals – from startups to established manufacturers – are invited to participate.

About FuzeHub

FuzeHub is a not-for-profit organization that connects New York’s small to medium-sized manufacturing companies to the resources, programs, and expertise they need for technology commercialization, innovation, and business growth. Through our custom assessment, matching, and referral platform, we help companies navigate New York’s robust network of industry experts at Manufacturing Extension Partners centers, universities, economic development organizations, and other providers. FuzeHub is the statewide New York Manufacturing Extension Partnership Program (MEP) center, supported by Empire State Development’s Division of Science, Technology & Innovation. For more information on FuzeHub, visit www.fuzehub.com.

Media Contact
John Mackowiak
jmackowiak@martingroupmarketing.com
518.618.1175

SOURCE: FuzeHub

View the original press release on ACCESS Newswire

STONY BROOK, NY / ACCESS Newswire / July 24, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (“Applied DNA” or the “Company”), a leader in synthetic DNA manufacturing powered by scalable PCR platforms, today announced it received a seventh follow-on order valued at more than $600,000 for a multi-gram quantity of LineaDNA™. The follow-on order was placed by a global manufacturer of in vitro diagnostics (IVDs) under a long-standing supply agreement for the bulk manufacture of LineaDNA used as a functional component of a cancer diagnostic test. Deliveries are scheduled across four quarterly shipments beginning in the second quarter of fiscal 2026 (ending March 31, 2026).

About the LineaDNA™ and LineaIVT™ Platforms
The LineaDNA platform is a proprietary, cell-free DNA production system leveraging Applied DNA’s deep expertise in large-scale PCR. Unlike conventional plasmid-based DNA production methods, the LineaDNA platform produces high-fidelity DNA that is free of adventitious sequences, rapidly scalable, and readily amenable to chemical modification. It can generate DNA from 100 base pairs to 20 kilobases in quantities from milligrams to grams under RUO, GLP, and GMP quality grades.

The LineaIVT platform provides a streamlined solution for mRNA production by integrating DNA IVT template manufacturing from the LineaDNA platform with the Company’s proprietary LineaRNAP enzyme. This platform’s unique integrated approach bypasses plasmid DNA as a starting material, prevents or reduces double-stranded RNA (dsRNA) contamination, and simplifies mRNA production workflows.

About Applied DNA Sciences
Applied DNA Sciences is a biotechnology company with over 20 years of experience in developing and commercializing polymerase chain reaction (PCR)-based applications for DNA production. Through its majority-owned subsidiary, LineaRx Inc., the Company is commercializing its LineaDNA™ and LineaIVT™ platforms to enable the manufacture of next-generation nucleic acid-based therapies.

Visit adnas.com for more information. Follow us on X and LinkedIn. Join our mailing list.

Forward-Looking Statements
The statements made by Applied DNA Sciences in this press release may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. These forward-looking statements are based largely on the Company’s expectations and projections about future events and future trends affecting our business and are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Actual results could differ materially from those projected due to the Company’s history of net losses, limited financial resources, substantial doubt regarding its ability to continue as a going concern, unknown future ability to continue its listing on the Nasdaq Capital Market, unknown future demand for its biotherapeutics products and services, the unknown amount of revenues and profits that will result from our LineaDNA and/or LineaIVT platforms, the fact that there has never been clinical trial material and/or a commercial drug product produced utilizing the LineaDNA and/or LineaIVT platforms, as well as various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including its Annual Report on Form 10-K filed on December 17, 2024, its Quarterly Reports on Form 10-Q filed on February 13, 2025, and May 15, 2025, and other reports it files with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.

Contacts:
Investor Relations contact: Sanjay M. Hurry, 917-733-5573, sanjay.hurry@adnas.com
Program contact: Brian Viscount, 631-240-8877, brian.viscount@adnas.com
Web: https://investors.adnas.com/
X: @APDN

SOURCE: Applied DNA Sciences

View the original press release on ACCESS Newswire

NEW YORK CITY, NEW YORK / ACCESS Newswire / July 24, 2025 / With a single stroke of his pen, President Donald Trump changed the world. How so? By signing into law the GENIUS Act, the first major piece of federal cryptocurrency legislation in U.S. history. In that moment, digital assets gained something they had long been denied: legal legitimacy in the world’s largest economy.

This wasn’t just a symbolic gesture-it was a systemic shift. For the first time, the U.S. financial system now has a federally sanctioned framework for stablecoins. Crypto is no longer a fringe experiment or tolerated anomaly. It’s been formally embraced, integrated, and empowered by the highest levels of policymaking.

And make no mistake, this law doesn’t just validate cryptocurrency-it sets the stage for an all-out transformation to a global digital economy. Don’t underestimate the long game. Trump’s signature didn’t just loosen the valve to lubricate digital commerce; it greased the wheels for global manufacturers to have the practical ability to comply with sustainability mandates that, until now, have felt more punitive than inspirational.

Before the ink even dried, companies around the world were likely embracing what the GENIUS Act truly delivered: unrestricted access to legitimized digital tools that can accelerate sustainability compliance and transparency, not just for optics, but for action. With blockchain-integrated platforms, companies now have the power to prove compliance through tools that are measurable, verifiable, and scalable.

A Token That Corrects the Market

Manufacturers won’t be the only ones rewarded for their commitments. For SMX (NASDAQ: SMX), Trump’s signing the Genius Act into law is also nothing short of transformative. For years, SMX has been at the forefront of innovation. Its molecular marking technology has redefined how brands can trace materials throughout their entire lifecycle-from extraction to recycling.

Now, with stablecoins legally recognized in the world’s largest economy, SMX can bring this technology to the mainstream of manufacturing, no longer constrained by legislative ambiguity. The result? A new kind of marketplace, one where environmental impact is no longer estimated, but proven. Quantified. Tokenized.

With its creation of the Plastic Cycle Token (PCT), SMX has introduced something the sustainability world has long lacked: a digital asset rooted in proof, not promises. Traditional systems have relied on good intentions and unverifiable claims. The carbon credit market, although well-intentioned, has faced persistent issues, including double-counting, unclear verification, and a lack of transparency. Without digital infrastructure, it struggled to scale. Given the magnitude of the task, understandably so. And learning from mistakes, history does not need to repeat.

At its core, the PCT is the infrastructure that the carbon market never had. It’s not just a platform-it’s a fully operational ecosystem. It links molecular-level data from real-world materials with blockchain-backed proof, creating a tradable, tokenized unit of sustainability. The PCT doesn’t require trust; it replaces it with truth. It doesn’t estimate impact, it verifies it. This is a foundational system built not for promises, but for performance, and it gives corporations a reason to participate not out of obligation, but out of opportunity.

SMX’s PCT Can Legitimize Markets

The best news- SMX has already demonstrated that its technology can mark and trace rubber, plastics, textiles, liquids, and other materials at industrial scale. It’s already been used to authenticate natural rubber from tree to tire. The data exists. The digital layer is built. The tokens are ready.

Until now, the one missing piece was market legitimacy. Just a day ago, the Plastic Cycle Token could have been dismissed by skeptics as an ambitious, speculative concept-innovative, yes, but unproven in the eyes of global markets. That changed overnight. With legislation like the GENIUS Act establishing stablecoins as federally recognized digital instruments, the PCT is no longer operating in a gray zone. It’s operating in a legitimized digital marketplace, with the full weight of U.S. regulatory infrastructure now recognizing the value and validity of asset-backed tokens.

Thanks to the GENIUS Act and the broader suite of crypto and digital asset legislation now moving through Congress, that barrier has been cleared. Crypto and digital are no longer a question mark. It’s recognized. It’s viable. And with regulatory clarity now in place, the PCT is not just ready-it’s positioned. Positioned to enter a legitimized, compliant, and increasingly interoperable digital marketplace.

Partnership Infrastructure In Place

And perhaps most importantly, there’s no shortage of potential digital platform partners capable of accelerating PCT adoption. With a validated regulatory framework now established, these platforms can step in to provide the 24/7 liquidity and marketplace efficiency that digital assets demand. In short, the rails are built, the token is live, and the market is finally ready to receive it.

What sets the Plastic Cycle Token apart isn’t just its tech. It’s what it represents. It isn’t a speculative coin. It’s not a credit for something you might do one day. It’s a digital certificate backed by molecular data and real-world circularity. If the carbon market had been built on this kind of infrastructure, it might have fulfilled its promise. Instead, it buckled under the weight of unverifiability.

That’s why the PCT is a game changer-and why regulators, investors, and global brands must begin to recognize and understand its importance. This is not an abstract theory or marketing gimmick. It’s a tool designed to embed accountability into sustainability and make environmental responsibility a tradeable, measurable, and revenue-generating reality. It’s an ESG asset born in the lab, verified on the blockchain, and ready to be traded.

And we’re not talking about collecting bottles and cans. We’re talking about providing major companies with the ability to value tons of plastic waste, compressed into a single token. The Plastic Cycle Token isn’t about hobby-level recycling. It’s about creating a system where companies can monetize massive amounts of plastic waste and do so with traceable, tradable credibility. The incentive to act isn’t just moral-it’s financial. And that’s what makes this opportunity so powerful.

Know this: Trump’s signature did more than validate Bitcoin or stablecoins. It validated the architecture that underpins digital value. It set the stage for tokenized assets to become mainstream financial instruments. It created the political momentum necessary to establish a legal, liquid market for real-world asset tokens.

And that turns the Plastic Cycle Token from a concept into a commodity.

The Future Sustainability Market Arrives

With every piece of plastic tagged, traced, and verified, a token can be created-one that represents measurable environmental impact with the kind of transparency regulators demand and the kind of precision markets crave. It transforms each verified input into a marketable, tradeable digital asset, reinforcing trust through data and creating financial incentive through scale.

For the first time, sustainability can be measured in a unit that has value, verifiability, and liquidity. So, the next step isn’t to further discuss SMX’s innovation-it’s about implementing it. SMX’s Plastic Cycle Token isn’t about commercial bragging rights. It’s about offering a viable path forward for sustainability markets that have struggled to earn trust, scale, or impact.

Now, as the digital economy embraces real-world asset tokenization, and with regulators clearly opening the door to transparent and tradable ESG assets, the Plastic Cycle Token arrives not just as a solution, but it arrives as a signal. A signal that accountability, circularity, and profitability no longer need to exist in tension.

Thanks to Trump’s signing of the Genius Act, the market is open. And thanks to SMX, the technology to meet its demand is already here.

About SMX (Security Matters) Public Limited Company
As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

Forward-Looking Statements
The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: matters relating to the Company’s fight against abusive and possibly illegal trading tactics against the Company’s stock; successful launch and implementation of SMX’s joint projects with manufacturers and other supply chain participants of steel, rubber and other materials; changes in SMX’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; SMX’s ability to develop and launch new products and services, including its planned Plastic Cycle Token; SMX’s ability to successfully and efficiently integrate future expansion plans and opportunities; SMX’s ability to grow its business in a cost-effective manner; SMX’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of SMX’s business model; developments and projections relating to SMX’s competitors and industry; and SMX’s approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; any lingering effects of the COVID-19 pandemic on SMX’s business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which SMX operates; the risk that SMX and its current and future collaborators are unable to successfully develop and commercialize SMX’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that SMX is unable to secure or protect its intellectual property; the possibility that SMX may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in SMX’s filings from time to time with the Securities and Exchange Commission.

Media Contact For This Release:
info@hawkpointmedia.com

SOURCE: SMX (Security Matters) Public Limited

View the original press release on ACCESS Newswire

Securitization comprised of green bonds reflects EdgeCore’s commitment to sustainable development and operations practices

DENVER, CO / ACCESS Newswire / July 24, 2025 / EdgeCore Digital Infrastructure, a wholesale data center developer, owner and operator, today announced the completion of an asset-backed securitization (ABS), totaling $235 million. Proceeds will be used to refinance construction loans and fund future green data center development.

This issuance is backed by EdgeCore’s fully stabilized PH01 data center, which is comprised of 26 MW of IT capacity and is fully leased to a single hyperscale tenant. PH01 is located on EdgeCore’s flagship data center campus in Greater Phoenix.

“EdgeCore’s rapid, exponential growth continues to be supported by the strong financial backing of our owner, Partners Group, and our ability to raise funds through various financing strategies,” said Lee Kestler, CEO, EdgeCore Digital Infrastructure. “Today’s announcement of a significantly oversubscribed, $235 million asset-backed securitization and establishment of a corresponding master trust is a strong first step in a series of ABS issuances which will fund the development of high-density data center campuses across our portfolio.”

This ABS is comprised of designated green bonds, issued in accordance with EdgeCore’s Green Financing Framework and aligned with the Green Bond Principles of the International Capital Markets Association. Second party opinion was provided by Sustainalytics.

“We prioritized the inclusion of green bonds in this $235 million ABS transaction as part of EdgeCore’s commitment to designing and operating green data center campuses,” said Julie Brewer, EVP of Finance, EdgeCore Digital Infrastructure. “The strength of the S&P ratings associated with this securitization are proof that the financial market continues to see value and stability in EdgeCore and the data center industry as a whole.”

EdgeCore’s ABS was significantly oversubscribed and received S&P ratings of A- and BBB- for its two tranches of notes.

Last month, EdgeCore announced the acquisition of 697 acres of land in Louisa County, Virginia, on which the company intends to develop a data center campus capable of supporting over 1.1GW of power. In May 2025, EdgeCore announced that it had acquired another 44 acres of land in Greater Phoenix, which will be used to expand its total data center capacity in Mesa, AZ to over 450MW of capacity.

About EdgeCore Digital Infrastructure

EdgeCore Digital Infrastructure serves the world’s largest cloud and internet companies with both ready-for-occupancy and build-to-suit data center campuses that are designed for density. Privately held and backed by committed equity, EdgeCore enables hyperscale customer requirements by proactively investing in regions that provide the land and power necessary to support and scale AI and cloud technology. While working thoughtfully with the communities in which we do business, our data center campuses are built at scale to meet key performance specifications, safety metrics and sustainability objectives. EdgeCore has data center campuses in six North American markets with plans to expand into new regions in 2025 and beyond. For more information, please visit edgecore.com.

Contact
Courtney Gaudet
EdgeCore Digital Infrastructure
courtney.gaudet@edgecore.com

SOURCE: EdgeCore Digital Infrastructure

View the original press release on ACCESS Newswire

This unique cellular activity may help restore energy balance and improve essential cell functions such as protein synthesis and membrane stability in diseases like Parkinson’s ALS Alzheimer’s and Progeria where mitochondrial failure and oxidative stress drive progression

MIAMI, FL / ACCESS Newswire / July 24, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or Telomir, a preclinical-stage biotechnology company developing therapies that target the root causes of biological aging and age-related diseases, today announced new preclinical results showing that its lead compound, Telomir-1, restored mitochondrial function without triggering oxidative stress or cell proliferation in human cells derived from a patient with Hutchinson-Gilford Progeria Syndrome (HGPS).

The study was conducted in collaboration with Smart Assays Biotechnologies Ltd., a leading preclinical contract research organization specializing in advanced cell-based models and drug mechanism profiling. Researchers used a Progeria human fibroblast cell line that models the mitochondrial dysfunction, oxidative stress, and premature aging associated with this rare genetic disorder.

“This cell line-specific metabolic response may reflect selective engagement of mitochondrial pathways-an encouraging signal for therapeutic programs targeting neurodegenerative diseases where mitochondrial dysfunction drives progression,” said Dr. Raphael Mayer, CEO of Smart Assays. “For example, the compound’s mode of action may be relevant to Parkinson’s disease, where mitochondrial stress and redox imbalance directly contribute to dopaminergic neuron loss. We’ve worked with many companies developing mitochondrial-targeted therapies, and Telomir-1 stands out with one of the most distinctive profiles we’ve seen.”

A Targeted Approach to Cellular Energy Restoration
Mitochondria are the “power plants” of the cell, responsible for generating the energy needed for survival, repair, and communication. In many serious diseases-including Progeria, Werner’s disease, ALS, Parkinson’s, and Alzheimer’s-mitochondria lose function, and cells cannot produce the energy required to maintain health.

While restoring mitochondrial energy is a promising strategy, doing so without increasing reactive oxygen species (ROS) or causing genetically unstable cells to divide is critical. In this study, Telomir-1 demonstrated a unique activity profile: restoring energy selectively in diseased cells, without significantly affecting control fibroblasts.

In this Progeria model, Telomir-1:

• Significantly increased mitochondrial energy production (WST-1 assay):
  Indicating improved energy generation in metabolically compromised cells-a fundamental requirement for cellular repair and function.

• Did not increase the number of live cells (Calcein staining):
  Suggesting Telomir-1 restored energy without triggering cell division, which may offer important safety advantages in fragile or genetically damaged cells.

• Reduced reactive oxygen species (ROS) under both basal and metal-induced stress conditions: ROS are damaging molecules linked to mitochondrial dysfunction and cellular decline. In this model, reducing ROS is especially important, as oxidative stress contributes to degeneration in genetically unstable cells such as those seen in Progeria and other mitochondrial-driven diseases.

• Showed a stronger effect in Progeria cells than in healthy fibroblast controls:
  Indicating a potentially selective effect in diseased tissue, with reduced risk of unwanted stimulation in healthy cells.

“In Progeria and other conditions where cells are genetically unstable, restoring function without forcing replication is an important safety consideration,” said Dr. Itzchak Angel, CSA at Telomir. “Generally, increasing mitochondrial activity is associated with an increase in ROS production, which can be harmful to the cell.Telomir-1’s ability to boost energy production, while reducing ROS and without triggering proliferation sets it apart from many compounds in this space.”

Therapeutic Potential Across Mitochondrial-Driven Diseases
The mechanism observed in this study may have broader relevance across diseases where mitochondrial failure plays a central role, including:

• Parkinson’s disease: Mitochondrial dysfunction contributes to dopaminergic neuron loss and motor decline. Telomir-1 may support neuron survival by improving cellular energy.

• ALS (Amyotrophic Lateral Sclerosis): Motor neurons rely on mitochondrial integrity. Restoring energy without overstimulating growth could help stabilize cell function.

• Alzheimer’s disease: Linked to early mitochondrial decline and oxidative stress, which precede memory loss and cognitive deterioration.

• Progeria (HGPS): A pediatric aging disorder driven by oxidative and mitochondrial damage-offering a focused model for evaluating therapeutic impact.

“We continue to see Telomir-1 produce consistent, differentiated results across multiple models,” said Erez Aminov, CEO of Telomir. “The ability to restore mitochondrial function without increasing ROS or activating cell replication may represent a fundamentally new approach to treating complex diseases rooted in energy failure.”

Targeted Clinical Strategy Underway
Telomir has completed multiple preclinical studies in human cell models and in vivo systems and is finalizing IND-enabling work for Telomir-1. The company continues to evaluate several possible initial clinical indications, guided by data, unmet medical need, and regulatory strategy.

“We’re now focused on selecting the right disease target that aligns with our mechanism and allows us to deliver the greatest clinical impact,” added Aminov. “We look forward to sharing our next steps as we move toward the clinic.”

Cautionary Note Regarding Forward-Looking Statements
This press release, statements of Telomir’s management or advisors related thereto, and the statements contained in the news story linked in this release contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1.

Any forward-looking statements in this press release are based on Telomir’s current expectations, estimates and projections only as of the date of this release. These and other risks concerning Telomir’s programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which are on file with the SEC and available at www.sec.gov. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact Information
Helga Moya
info@telomirpharma.com
(786) 396-6723

SOURCE: Telomir Pharmaceuticals, Inc

View the original press release on ACCESS Newswire

HOUSTON, TEXAS / ACCESS Newswire / July 24, 2025 / EON Resources Inc. (NYSE American:EONR) (“EON” or the “Company”) is an independent upstream energy company with 20,000 leasehold acres comprising two fields in the Permian Basin in southeast New Mexico. Today, the Company provides insight into its preliminary second-quarter 2025 results and other actions reflecting a rebound in production after temporary impact from field actions; a reduction in field operating expenses, G&A costs and interest expense in Q2; the contracting of a third service rig in the Grayburg-Jackson Field; and the integration of the newly acquired South Justis Field.

Grayburg-Jackson Field – Q2 actions

During the second quarter of 2025 and through this press release date, EON has performed several actions in the Grayburg-Jackson Field (“GJF”) to increase profitability going forward. While some of the actions impacted production during Q2, the production rebounded late June to return to a stable production level going into July. The production trends and highlights of the activities in the GJF in Q2 and into July include:

• Since acquisition of the GJF through the end of Q1 2025, the gross barrels of oil per day (“BOPD”) produced was stabilized and maintained at approximately 935 BOPD over the 15-month period. During Q2 2025, BOPD temporarily dropped by approximately 100 BOPD resulting in an 835 total BOPD average for the second quarter. In the last third of June and into July, the production returned to an average 935 BOPD run rate.

• The negative impacts on Q2 production resulted from an equal combination of on-going water injection mechanical problems and downtime required to perform acid treatments and well servicing work to return wells to production.

• The rebound in production during the last third of June and into July is a result of 12 wells having been treated with acid utilizing an improved proprietary chemical and well servicing work to return additional wells to production.

• To return wells to production, the Company ramped up the well service rigs in the GJF. The Company contracted a second well service rig in June 2025, in order to return a number of down wells to production. The two rigs have serviced 27 additional wells. A third well service rig was employed in July 2025, which started in the GJF in mid-July. The third well service rig is to primarily focus on saltwater injection wells to sustain long-term production. The Company expects to utilize three well service rigs for the foreseeable future to increase production over the next several quarters.

• Water injection performance was worse than anticipated. The poor performance combined with contractor delays in installation of a critical replacement water line, impacted Q2 2025 production. Crews have been mobilized to replace and install injection flowlines for a major portion of the GJF.

• The field team is making good progress to replace our water injection supply lines, returning down wells to production and repairing down water injection wells. In all, the Company expect to add another 100 BOPD in August 2025 by observing the same successful improvements made in June and July 2025.

Insight to preliminary Q2 2025 financial results

While the oil revenues from production were impacted in Q2 2025, the total revenues for Q2 2025 were little changed from Q1 2025. The impact was mitigated by the Company’s hedging position. The Company recovered approximately $290K of cash as approximately 75% of the oil was hedged at $70.00 per barrel. The non-cash hedge portion had a positive revenue impact of approximately $500K.

Mitigating the temporary production impact, cost reduction actions in late 2024 and into 2025 reduced Q1 2025 lease operating expenses (“LOE”), G&A costs and interest expense. The cost reduction trend continued in Q2 2025. Approximately $130k of combined costs were reduced in Q2 2025 from these three categories.

The Company’s balance sheet improved in Q2 2025. Former private loan obligations of the Company and related warrant liabilities were exchanged in full for long-term Convertible Notes by the end of Q2 2025. The resulting impact of the exchange was to reduce current liabilities by approximately $6 million. A portion of the Convertible Notes were converted to Class A common shares in Q2 2025 resulting in an overall debt reduction of approximately $3 million during the quarter with a concurrent increase in shareholder equity.

South Justis Field acquisition completed in Q2

On June 20, 2025, EON announced its acquisition of the South Justis Field (“SJF”) in the Permian Basin. Since acquiring the field, the production has remained stable at over 100 BOPD from 19 actively producing wells. The Company plans to return an additional 30 wells to production over the next year, and is adding a second well service rig to the SJF to return down wells to production. The production from the reactivated wells is expected to average 5-10 BOPD per well, yielding field wide production of 250 to 400 BOPD. The SJF is expected to initially produce approximately $100K of cash from the operations, and increase as new wells are reactivated.

More information on South Justis Field can be found on the EON website under the Company’s operations page at the SJF operations page; the South Justis Field acquisition press release; and the South Justis Field investor call deck.

Horizontal drilling program at GJF being poised for 2026

In February 2025, EON announced its horizontal drilling program, which identified 50 well locations to be drilled over several years.

“Our horizontal drilling program is on schedule to commence during the first quarter of 2026,” said Dante Caravaggio, President and CEO of the Company. “Initial and preliminary engineering and construction work has begun in the current quarter and will be completed by year-end. Each well is expected to produce 300 to 400 BOPD.”

“The ability to sell all produced oil is solid. Although there has been some short-term oil market tightness, and the U.S. Energy Information Administration (EIA) has forecasted crude output in the Permian Basin should rise from 13.2 million barrels a day to over 13.4 million barrels a day this year, our largest customer will take every barrel of oil we produce at market prices,” said Mitchell B. Trotter, CFO of the Company. “Oil in the Permian Basin in New Mexico grew by 14 percent in 2024, and it should continue to grow this year. We remain bullish on EON and the high upside potential of our fields.”

About the Grayburg-Jackson Oil Field Property

LH Operating, LLC (“LHO”), a wholly owned subsidiary of EON, operates its holdings in New Mexico of oil and gas waterflood production comprising 13,700 contiguous leasehold acres, 342 producing wells and 207 injection wells situated on 20 federal and 3 state leases in the Grayburg-Jackson Oil Field. The Grayburg-Jackson Oil Field is located on the Northwest Shelf of the prolific Permian Basin in Eddy County, New Mexico.

Leasehold rights of LHO include the Seven Rivers, Queen, Grayburg and San Andres intervals that range from as shallow as 1,500 feet to 4,000 feet in depth. The December 2024 reserve report from our third-party engineer, Haas and Cobb Petroleum Consultants, LLC (“Haas & Cobb” or “Cobb”), reflects LHO to have proven reserves of approximately 14.0 million barrels of oil and 2.8 billion cubic feet of natural gas. The mapped original-oil-in-place (“OOIP”) in the LHO leasehold is approximately 876 million barrels of oil in the Grayburg and San Andres intervals and 80 million barrels in the Seven Rivers interval for a total OOIP of approximately 956,000,000 barrels of oil.

Our primary production is currently from the Seven Rivers zone. In addition to proven reserves, the Company believes it may access an additional 34 million barrels of oil by adding perforations in the Grayburg and San Andres formations. With proven oil reserves of over 15 million barrels, combined with the potential 34 million additional barrels from the Grayburg and San Andres zones, LHO should produce oil and a revenue stream for more than two decades with a low decline rate.

About the South Justis Field Property

The South Justis Field (“SJF” or “Field”) is a carbonate reservoir, similar to the rest of the Permian. The Field was first developed in the 1960’s and had an initial production in the 6,000 BOPD range. The waterflood implemented at a cost of $40 million dollars in the 1990’s by a major oil company. The subsequent owners of the Field had higher priorities, which led to an increase in idle wells with downhole failures, thus allowing the production to drop dramatically. The Seller acquired the field and has reactivated several wells and increased the production of oil.

The SJF comprises 5,360 contiguous acres with 208 combined producing and injection wells with large spacing of 50 acres. The field is located in the Central Basin of the prolific Permian Basin in Lea County, New Mexico located approximately 100 miles from EON’s Grayburg-Jackson Oil Field property in Eddy County, New Mexico. Our rights include the Glorietta, Blinebry, Tubb, Drinkard and Fusselman intervals that range from 5,000 feet to 7,000 feet in depth. The original-oil-in-place (“OOIP”) is approximately 207 million barrels of oil.

About EON Resources Inc.

EON is an independent upstream energy company focused on maximizing total returns to its shareholders through the development of onshore oil and natural gas properties in the United States. EON’s long-term goal is to maximize total shareholder value from a diversified portfolio of long-life oil and natural gas properties built through acquisition and through selective development, production enhancement, and other exploitation efforts on its oil and natural gas properties.

EON’s Class A Common Stock trades on the NYSE American Stock Exchange (NYSE American:EONR) and the Company’s public warrants trade on the NYSE American Stock Exchange (NYSE American:EONR WS). For more information on EON, please visit the Company’s website: https://www.eon-r.com/

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to differ materially from what is expected. Words such as “expects,” “believes,” “anticipates,” “intends,” “estimates,” “seeks,” “may,” “might,” “plan,” “possible,” “should” and variations and similar words and expressions are intended to identify such forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Such forward-looking statements relate to future events or future results, based on currently available information and reflect the Company’s management’s current beliefs. A number of factors could cause actual events or results to differ materially from the events and results discussed in the forward-looking statements. Important factors – including the availability of funds, the results of financing efforts and the risks relating to our business – that could cause actual results to differ materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time on EDGAR (see www.edgar-online.com) and with the Securities and Exchange Commission (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Investor Relations

Michael J. Porter, President
PORTER, LEVAY & ROSE, INC.
mike@plrinvest.com

SOURCE: EON Resources Inc.

View the original press release on ACCESS Newswire

TORONTO, ON / ACCESS Newswire / July 24, 2025 / Eskay Mining Corp. (“Eskay” or the “Company”) (TSXV:ESK)(OTC PINK:ESKYF)(Frankfurt:KN7)(WKN:A0YDPM) is pleased to provide an update on its aggressive prospecting and sampling program at its 100% controlled and consolidated Eskay Project in the heart of the Golden Triangle, British Columbia. The Company’s geological team has systematically prospected and sampled the Vermillion, TM, Red Lightning, and Big Red Zones surrounding Unuk Finger Mountain in the southern extent of the Property where high grade gold veins were discovered in 2024.

Veining in these areas has been found to be much more extensive than previously recognized. To date, 268 surface rock samples have been collected and delivered to MSA Labs. Of the 268 surface rock samples, 29 channel samples were cut across an aggregate of 25.25 metres in the Vermillion Zone across vein zones of known gold mineralization hosted in planar and sheeted quartz veining (Figure 1).

Continued prospecting and mapping in the Vermillion Zone has led to the discovery of in situ visible gold and electrum mineralization in samples A0514497 (Figure 2) and A0514398 (Figure 3), hosted in planar quartz manganese-carbonate veins with accessory pyrrhotite, chalcopyrite, bismuthanite, and wolframite. Sample A0514497 with visible gold mineralization was collected 5 metres northeast and on trend of 2024 sample C970477 which returned assay values of 205 g/t gold and 118 g/t silver (see News Release dated October 8, 2024). The second visible gold sample A0514398 was discovered approximately 220 metres south-southwest of sample A0514497 in a newly discovered sub-parallel vein zone. Assays for these samples are pending.

Prospecting across all zones surrounding Unuk Finger mountain has discovered new flat lying, sheeted and planar shear quartz vein zones that appear relatable to veining that returned high gold values in 2024. Veins of similar style have been observed over 600 metres vertically and 500 by 2000 metres horizontally. The style of the quartz-sulfide veins observed in these zones strongly resembles those at Goliath’s Surebet gold project in the southern Golden Triangle. Like at Surebet, there is an Eocene aged intrusion at Eskay that appears to be closely associated with mineralization.

The first batch of assays from surface rocks collected in the Big Red and upper TM Zones are expected to be returned in the next 14 days.

Mapping and prospecting are ongoing in unison with drill target delineation.

Dr. Quinton Hennigh, P. Geo., a Director of the Company and its technical adviser, a qualified person as defined by National Instrument 43-101, has reviewed and approved the technical contents of this news release.

About Eskay Mining Corp:

Eskay Mining Corp (TSX-V:ESK) is a TSX Venture Exchange listed company, headquartered in Toronto, Ontario. Eskay is an exploration company focused on the exploration and development of precious and base metals along the Eskay rift in a highly prolific region of northwest British Columbia known as the “Golden Triangle,” 70km northwest of Stewart, BC. The Company currently holds mineral tenures in this area comprised of 177 claims (52,600 hectares).

All material information on the Company may be found on its website at www.eskaymining.com and on SEDAR+ at www.sedarplus.com.

For further information, please contact:

Mac Balkam
President & Chief Executive Officer
T: 416 907 4020
E: Mac@eskaymining.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements: This Press Release contains forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. When used in this document, the words “may”, “would”, “could”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions are intended to identify forward-looking statements. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties. Many factors could cause our actual results to differ materially from the statements made, including those factors discussed in filings made by us with the Canadian securities regulatory authorities. Should one or more of these risks and uncertainties, such as actual results of current exploration programs, the general risks associated with the mining industry, the price of gold and other metals, currency and interest rate fluctuations, increased competition and general economic and market factors, occur or should assumptions underlying the forward looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, or expected. We do not intend and do not assume any obligation to update these forward-looking statements, except as required by law. Shareholders are cautioned not to put undue reliance on such forward-looking statements.

Figure 1. Channel sampling through a zone of intense quartz shear veining at the Vermillion Zone.

Figure 2. In situ sample A0514497 with visible gold mineralization hosted in a quartz manganese-carbonate vein with pyrrhotite, chalcopyrite and wolframite.

Figure 3. In situ sample A0514398 with visible gold mineralization a quartz manganese-carbonate vein with pyrrhotite.

SOURCE: Eskay Mining Corp.

View the original press release on ACCESS Newswire

LONDON, UK AND VANCOUVER, BC / ACCESS Newswire / July 24, 2025 / CoTec Holdings Corp. (TSXV:CTH)(OTCQB:CTHCF) (“CoTec”) and Mkango Resources Ltd. (AIM:MKA)(TSXV:MKA) (“Mkango”) are pleased to announce a feedstock supply and pre-processing site share agreement between global electronics recycling company, Intelligent Lifecycle Solutions, LLC (“ILS”), and HyProMag USA, LLC (“HyProMag USA” or the “Project”) (the “Supply Agreement”).

• ILS will secure and store neodymium iron boron (“NdFeB”) feedstock from hard disk drives (“HDDs”) and other sources for HyProMag USA at the ILS pre-processing sites in Williston, South Carolina and Reno, Nevada (the “ILS pre-processing sites”) in advance of the commissioning of HyProMag USA’s advanced stage rare earth magnet recycling and manufacturing plant to be located in Dallas-Fort Worth, Texas (the “DFW Hub”)

• ILS will utilise the INSERMA ANOIA SL (“Inserma”) “3^rd generation” HDD magnet separation system at its pre-processing sites. An exclusive agreement was signed between the HyProMag Group and Inserma in September 2024^[i], and the Inserma technology is being rolled out across multiple jurisdictions

• The improved Inserma units provide fast, efficient magnet separation from HDDs for Hydrogen Processing of Magnet Scrap (“HPMS”) processing together with clean separation of the printed circuit board for immediate resale to 3^rd parties

• HyProMag USA is, inter alia, targeting HDD recycling geared to the growth of hyperscale data centers, which is expected to accelerate significantly in coming years

• HyProMag USA will include the ILS pre-processing sites in its detailed design and engineering. The ILS pre-processing sites will be able to source multiple feed types to provide supply feed to the Project’s magnet recycling and manufacturing hub in Dallas-Fort Worth. Other NdFeB feedstock sources being successfully processed to date by HyProMag include rotors from electric motors, wind turbine magnets, speaker assemblies and MRIs

• The Supply Agreement is expected to be the first in several supply agreements to be entered into by HyProMag USA as the Project advances to construction and commissioning

ILS is a global electronics recycling company processing electronic waste. It is a full-service IT asset disposition, electronics recycling and scrap purchasing company and is fully compliant in ISO 14001:2015, ISO 45001:2018 and “Responsible Recycling R2v3 Recycler” at its USA locations. Through ILS, HyProMag USA will provide full traceability on its products to support the “closed loop” circular economy and critical mineral supply chains within the United States.

The collaboration builds on the relationship established between ILS, HyProMag Limited (“HyProMag”) and the Magnetic Materials Group (“MMG”) at the University of Birmingham (“UoB”) through a number of European projects, including the 2020 Innovate UK^[ii] grant funded project, “Rare-Earth Recycling for E-Machines” (“RaRE”) project with Hydrogen Processing of Magnet Scrap (“HPMS”) in which HyProMag produced sintered NdFeB magnets from ILS feedstock, and HyProMag continues to work closely with ILS across multiple jurisdictions.

Julian Treger, CoTec CEO commented: “We are very excited to partner with ILS to grow the feed supply market in the United States and this collaboration is a first step in securing reliable long-term feed supply for HyProMag USA to sustain the Project as we advance towards construction. We believe that over time we will be able to build sufficient feedstock to sustain several magnet recycling and manufacturing hubs as the Company establishes itself as a key player in the US REE magnet industry.”

“HyProMag USA is progressing with its financing and detailed design and has the potential to supply the U.S. market with a sustainable, long term domestic supply of NdFeB permanent magnets, enabling the creation of secure, low carbon and traceable rare-earth supply chains.“

Will Dawes, Mkango CEO commented: “The agreement with ILS, coupled with the Inserma and HPMS technologies, creates a highly competitive and integrated circular solution for recycling of NdFeB from HDDs, encompassing procurement of HDDs via ILS, pre-processing using Inserma technologies, magnet liberation using HPMS and short-loop magnet manufacturing to produce a high value rare earth NdFeB magnet with a very low carbon footprint. Furthermore, the agreement kick-starts operations on the ground, securing NdFeB inventory in advance of commissioning of the DFW hub, and will facilitate increased engagement in USA markets as we move towards project development.”

Graham Davy, ILS CEO, commented: “We are delighted to be formalising our longstanding partnership with HyProMag. Lifecycle Solutions will be using our infrastructure to procure nationally rare earth material from government, manufacturing, and businesses as well as other recycling sources. Our clients value HyProMag’s short-loop, low carbon solution whist retaining critical materials within the USA. Lifecycle Solutions will use its R2 accredited facilities in South Carolina, Nevada, to acquire and preprocess Rare Earth material for HyProMag USA. Magnets recovered from its subsidiary hard disk drive business will also be supplied.”

HyProMag USA Feasibility Study
The Feasibility Study includes the DFW Hub, and two pre-processing facilities located in South Carolina and Nevada respectively^[iii]. In March 2025, HyProMag USA announced the expansion of the detailed engineering phase to include three HPMS vessels^[iv] and that it was initiating concept studies for further expansion and complementary “Long Loop” recycling^[v]. The DFW Hub’s annual production is expected to be 750 metric tons per annum of recycled sintered NdFeB magnets and 807 metric tons per annum of associated NdFeB co-products (total payable capacity – 1,557 metric tons NdFeB within five years of commissioning) over a 40-year operating life. It is expected the production facility will provide significant optionality to supply the U.S. market with additional NdFeB alloy powder while assisting in revitalising the U.S. magnet sector with the creation of 90-100 skilled magnet manufacturing jobs.

In March 2025, HyProMag USA announced the results of an independent ISO-Compliant product carbon footprint study which confirmed an exceptionally low CO₂ footprint of 2.35 kg CO₂ eq. per kg of NdFeB cut sintered block product.^[vi]

Ownership
HyProMag USA is owned 50:50 by CoTec and HyProMag Limited. HyProMag Limited is 100 per cent owned by Maginito Limited (“Maginito”), which is owned on a 79.4/20.6 per cent basis by Mkango and CoTec.

About HyProMag
HyProMag is commercializing HPMS recycling technology in the UK, Germany and the United States. HPMS technology was developed at the Magnetic Materials Group (MMG) at University of Birmingham, underpinned by approximately US$100 million of research and development funding, and has major competitive advantages versus other rare earth magnet recycling technologies, which are largely focused on chemical processes but do not solve the challenges of liberating magnets from end-of-life scrap streams – HPMS provides this solution.

About CoTec Holdings Corp.
CoTec is a publicly traded investment issuer listed on the Toronto Venture Stock Exchange (“TSX-V”) and the OTCQB and trades under the symbols CTH and CTHCF respectively. CoTec Holdings Corp. is a forward-thinking resource extraction company committed to revolutionizing the global metals and minerals industry through innovative, environmentally sustainable technologies and strategic asset acquisitions. With a mission to drive the sector toward a low-carbon future, CoTec employs a dual approach: investing in disruptive mineral extraction technologies that enhance efficiency and sustainability while applying these technologies to undervalued mining assets to unlock their full potential. By focusing on recycling, waste mining, and scalable solutions, the Company accelerates the production of critical minerals, shortens development timelines, and reduces environmental impact. CoTec’s strategic model delivers low capital requirements, rapid revenue generation, and high barriers to entry, positioning it as a leading mid-tier disruptor in the commodities sector.

For more information, please visit www.cotec.ca.

About Mkango Resources Ltd.
Mkango is listed on the AIM and the TSX-V. Mkango’s corporate strategy is to become a market leader in the production of recycled rare earth magnets, alloys and oxides, through its interest in Maginito, which is owned 79.4 per cent by Mkango and 20.6 per cent by CoTec, and to develop new sustainable sources of neodymium, praseodymium, dysprosium and terbium to supply accelerating demand from electric vehicles, wind turbines and other clean energy technologies.

Maginito holds a 100 per cent interest in HyProMag and a 90 per cent direct and indirect interest (assuming conversion of Maginito’s convertible loan) in HyProMag GmbH, focused on short loop rare earth magnet recycling in the UK and Germany, respectively, and a 100 per cent interest in Mkango Rare Earths UK Ltd (“Mkango UK”), focused on long loop rare earth magnet recycling in the UK via a chemical route.

Maginito and CoTec are also rolling out HPMS recycling technology into the United States via the 50/50 owned HyProMag USA LLC joint venture company.

Mkango also owns the advanced stage Songwe Hill rare earths project in Malawi (“Songwe”) and the Pulawy rare earths separation project in Poland (“Pulawy”). Both the Songwe and Pulawy projects have been selected as Strategic Projects under the European Union Critical Raw Materials Act. Mkango has signed a Business Combination Agreement with Crown PropTech Acquisitions to list the Songwe Hill and Pulawy rare earths projects on NASDAQ via a SPAC Merger.

For more information, please visit www.mkango.ca

Market Abuse Regulation (MAR) Disclosure
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 (‘MAR’), which has been incorporated into UK law by the European Union (Withdrawal) Act 2018. Upon the publication of this announcement via Regulatory Information Service, this inside information is now considered to be in the public domain.

Cautionary Note Regarding Forward-Looking Statements
This news release contains forward-looking statements (within the meaning of that term under applicable securities laws) with respect to Mkango and CoTec. Generally, forward looking statements can be identified by the use of words such as “plans”, “expects” or “is expected to”, “scheduled”, “estimates” “intends”, “anticipates”, “believes”, or variations of such words and phrases, or statements that certain actions, events or results “can”, “may”, “could”, “would”, “should”, “might” or “will”, occur or be achieved, or the negative connotations thereof. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. Such factors and risks include, without limiting the foregoing, the availability of (or delays in obtaining) financing to develop Songwe Hill, the Recycling Plants being developed by Maginito in the UK, Germany and the United States (the “Maginito Recycling Plants”), governmental action and other market effects on global demand and pricing for the metals and associated downstream products for which Mkango is exploring, researching and developing, geological, technical and regulatory matters relating to the development of Songwe, the ability to scale the HPMS and chemical recycling technologies to commercial scale, competitors having greater financial capability and effective competing technologies in the recycling and separation business of Maginito and Mkango, availability of scrap supplies for Maginito’s recycling activities, government regulation (including the impact of environmental and other regulations) on and the economics in relation to recycling and the development of the Maginito Recycling Plants, and the Pulawy separation plant and future investments in the United States pursuant to the proposed cooperation agreement between Maginito and CoTec, the outcome and timing of the completion of the Feasibility Studies, cost overruns, complexities in building and operating the plants, and the positive results of Feasibility Studies on the various proposed aspects of Mkango’s, Maginito’s and CoTec’s activities. The forward-looking statements contained in this press release are made as of the date of this news release. Except as required by law, the Company and CoTec disclaim any intention and assume no obligation to update or revise any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law. Additionally, the Company and CoTec undertake no obligation to comment on the expectations of, or statements made by, third parties in respect of the matters discussed above.

For further information on CoTec, please contact:
CoTec Holdings Corp.
Braam Jonker
Chief Financial Officer
braam.jonker@cotec.ca
+1 604 992-5600

For further information on Mkango, please contact:
Mkango Resources Limited
William Dawes
Chief Executive Officer
will@mkango.ca
+1 403 444 5979

Alexander Lemon
President
alex@mkango.ca

www.mkango.ca
@MkangoResources

SP Angel Corporate Finance LLP
Nominated Adviser and Joint Broker
Jeff Keating, Jen Clarke, Devik Mehta
UK: +44 20 3470 0470

Alternative Resource Capital
Joint Broker
Alex Wood, Keith Dowsing
UK: +44 20 7186 9004/5

The TSX Venture Exchange has neither approved nor disapproved the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any equity or other securities of the Company in the United States. The securities of the Company will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) and may not be offered or sold within the United States to, or for the account or benefit of, U.S. persons except in certain transactions exempt from the registration requirements of the U.S. Securities Act.

SOURCE: CoTec Holdings Corp.

View the original press release on ACCESS Newswire

With domestic travel on the rise and Australians looking to explore their own backyard, Liberty says personal loans could help turn travel dreams into reality.

MELBOURNE, AU / ACCESS Newswire / July 24, 2025 / Whether it’s discovering new corners of the country or returning to familiar favourites, Australians are embracing domestic travel in growing numbers.

Local getaways remain at the heart of how we holiday, with Roy Morgan reporting 57% of Australians are planning a domestic trip within the next 12 months.

Non-bank lender Liberty is helping to make those plans possible. Their personal loans could give Australians the freedom to say ‘yes’ to new adventures, sooner.

According to Communications Manager, Bernadine Pantarotto, Liberty remains ready to support everyday Australians to reach their travel goals.

“For nearly 30 years, our flexible solutions have helped over 900,000 free thinkers achieve their goals,” Ms Pantarotto said.

For those planning a long-awaited family trip or dreaming of a spontaneous getaway, a personal loan could offer the freedom to travel on their terms.

With flexible repayment options and fast approvals, Liberty makes it easier for borrowers to bring travel plans to life without the stress of upfront costs.

“We offer a quick and easy online application process to help borrowers get the funds they need,” Ms Pantarotto explained.

“Our speedy process means borrowers can get a personalised rate in minutes. In some cases, same-day funding upon approval may also be available,” Ms Pantarotto said.

For some, travel might be one of the most rewarding ways to recharge and reconnect – and personal loans could help them take a well-deserved break without breaking the bank.

A non-bank lender established on the values of fairness and inclusion, Liberty takes a personalised approach to lending.

“Liberty considers a range of factors to help those who might have more complex needs, including borrowers with imperfect credit histories or variable income sources,” Ms Pantarotto said.

Borrowers could also use personal loans to bring other ideas to life. A personal loan could also help borrowers plan a wedding or special event, cover medical expenses, or upgrade their home.

About Liberty
As one of Australia’s leading non-bank lenders, Liberty offers innovative solutions to support customers with greater choice. Over more than 27 years, this free-thinking approach to loan solutions has seen more than 900,000 customers across a wide range of home, car, business and personal loans, as well as SMSF lending and insurance. Liberty remains the only non-bank lender with an investment-grade credit rating offering custom and prime solutions to help more people get financial.

Approved applicants only. Lending criteria apply. Fees and charges are payable. Liberty Financial Pty Ltd ACN 077 248 983 and Secure Funding Pty Ltd ABN 25 081 982 872 Australian Credit Licence 388133, together trading as Liberty Financial.

Contact
Laura Orchard
Media Coordinator
P: +61 3 8635 8888
E: mediaenquiries@liberty.com.au

SOURCE: Liberty

View the original press release on ACCESS Newswire

RED BANK, NJ / ACCESS Newswire / July 23, 2025 / Tharimmune, Inc. (the “Company” and “Tharimmune”) (Nasdaq Capital Market:THAR), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced the pricing of a registered direct public offering (the “RD Offering”) with certain purchasers, under the Shelf Registration Statement (as defined below), of up to $1.74 million of the Company’s securities (the “Securities”) consisting of (i) 414,331 shares of Common Stock, par value $0.0001 per share (the “Common Stock”) and 559,910 pre-funded warrants to acquire shares of Common Stock (the “RD Pre-Funded Warrants”), and (ii) 974,241 warrants to acquire shares of Common Stock at the exercise price of $1.66 per share (the “RD Common Warrant”), at the price of $1.786 per unit comprised of one share of Common Stock or RD Pre-Funded Warrant and RD Common Warrant purchased, which shall be effected pursuant to the terms of that certain Securities Purchase Agreement (the “RD SPA).

Strategic Investors and Placement Details

Gross proceeds from the offering are expected to be approximately $1.74 million before deducting placement agent fees and estimated offering expenses. Tharimmune intends to use the net proceeds of the offering for working capital and general corporate purposes.

President Street Global, LLC is acting as the exclusive placement agent, on a reasonable best-efforts basis for the offering.

The closing of the offering is expected to occur on or about July 25, 2025, subject to satisfaction of customary closing conditions.

Regulatory Details

In relation to the RD Offering, a shelf registration statement on Form S-3 (File No. 333-270684, the “Shelf Registration Statement”) relating to the securities being offered in the RD Offering was previously filed with the U.S. Securities and Exchange Commission (the “SEC”) and became effective on March 24, 2023. [In relation to the RD Offering, the shares of common stock and shares underlying the pre-funded warrants are being offered only by means of a prospectus]. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the public offering have been filed with the SEC. A final prospectus supplement and an accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. When available, copies of the final prospectus supplement and accompanying prospectus relating to the public offering will be available by contacting President Street Global, LLC by telephone at 1-646-740-3646. Before you invest, you should read the preliminary prospectus supplement and accompanying prospectus, together with the information incorporated by reference therein, for more complete information about the Company and the proposed offering. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

Additionally, the RD Common Warrants sold in the RD Offering are offered under Section 4(a)(2) of the Securities Act of 1933, as amended, and Regulation D thereunder. The RD Common Warrants and underlying shares are not registered under the Securities Act or state securities laws. The Company has agreed to file a resale registration statement covering these securities to enable their future trading upon registration or qualification under applicable laws.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Tharimmune, Inc.

Tharimmune is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology, inflammation and oncology. Its lead clinical asset, TH104, is being developed for a specific indication via a 505(b)2 pathway for respiratory and/or nervous system depression in military personnel and chemical incident responders who may encounter environments contaminated with high-potency opioids. The expanded pipeline includes other indications for TH104, such as chronic pruritus in primary biliary cholangitis and TH023, a new approach to treating autoimmune diseases along with an early-stage multispecific biologic platform targeting unique epitopes against multiple solid tumors through its proprietary EpiClick^™Technology. The Company has a license agreement with OmniAb, Inc. to access their antibody discovery technology for targeting specified disease markers. Tharimmune continues to position itself as a leader in patient-centered innovation while working to deliver long-term value for shareholders. For more information, visit: www.tharimmune.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this press release, including statements regarding the timing and design of Tharimmune’s future Phase 2 trial, Tharimmune’s strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “depends,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “target,” “should,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Factors that may cause such differences, include, but are not limited to, those discussed under Risk Factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2024 and other periodic reports filed by the Company from time to time with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this release. Subsequent events and developments may cause the Company’s views to change; however, the Company does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this release.

Contacts:

Tharimmune, Inc.
ir@tharimmune.com

SOURCE: Tharimmune Inc.

View the original press release on ACCESS Newswire